Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | KIFC1 | Q9BW19 | 4/20 | 0.48 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.48 |
| ▸ | LCK | P06239 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | GLS | O94925 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3053216 | 0.88 | SCD (0.72) | SCDKDM4EKIFC1LCKNPC1 | |
| SCHEMBL3045262 | 0.85 | SCD (0.59) | SCDKDM4ECHRM4LCKMEN1 | |
| SCHEMBL3045817 | 0.85 | SCD (0.74) | SCDKDM4ELCKNPC1CSNK1D | |
| SCHEMBL3585444 | 0.83 | KDM4E (0.63) | SCDKDM4ECHRM4LCKNPC1 | |
| SCHEMBL3592271 | 0.79 | KDM4E (0.69) | SCDKDM4ELCKNPC1MEN1 | |
| SCHEMBL3577814 | 0.79 | SCD (0.74) | SCDKDM4ELCKNPC1CSNK1D | |
| SCHEMBL3593815 | 0.78 | SCD (0.76) | SCDKDM4ELCKNPC1MAOB | |
| SCHEMBL13082534 | 0.76 | CHRM4 (0.62) | SCDCHRM4NPC1MAOBKMT2A | |
| SCHEMBL3579438 | 0.75 | SCD (0.79) | SCDLCKNPC1CSNK1DMAOB | |
| SCHEMBL14385163 | 0.75 | KDM4E (0.51) | SCDKDM4ECHRM4LCKNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8236835-B2 | Heterocyclic inhibitors of stearoyl-CoA desaturase | NOVARTIS AG (CH) | 2012-08-07 | — | — | US | disclosed |
| US-20100029718-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029718-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | SCD 1/4885KDM4E 683/4885KIFC1 3439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.